AbbVie Inc. (FRA:4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 291.67B |
| Revenue (ttm) | 53.08B |
| Net Income (ttm) | 3.84B |
| Shares Out | n/a |
| EPS (ttm) | 2.16 |
| PE Ratio | 75.87 |
| Forward PE | 14.44 |
| Dividend | 5.88 (3.71%) |
| Ex-Dividend Date | n/a |
| Volume | 303 |
| Average Volume | 190 |
| Open | 161.80 |
| Previous Close | 160.60 |
| Day's Range | 161.40 - 163.00 |
| 52-Week Range | 141.80 - 203.05 |
| Beta | n/a |
| RSI | 41.83 |
| Earnings Date | Apr 25, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl...
3 Stocks That Will Profit From Trump's Drug Price Cut
On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...
Is It Time To Buy AbbVie Stock At $180?
AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This prot...
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV
NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class...
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
NEW YORK , May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV du...
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
Jim Cramer thinks that the bond market now offers a clearer risk-reward trade-off than so-called "safety" stocks, warning that rising 10-year Treasury yields and a political "wild card" in Washington ...
Jim Cramer talks good companies getting pummeled by rising interest rates
'Mad Money' host Jim Cramer talks opportunity stocks as rising interest rates weigh on some equities.
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ETCompany ParticipantsJeff Stewart - EVP and Chief Commercialization...
Three Stock Lunch: Advanced Micro Devices, Abbvie and Tesla
Scott Nations, Nations Indexes president, joins 'Power Lunch' to discuss Nations' investing take on three stocks: Advanced Micro Devices, Abbvie and Tesla.
AbbVie wins approval of Emrelis for non-small cell lung cancer
Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's
The Investment Committee debate the latest Calls of the Day.
Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Contact Levi & Korsinsky Before June 3, 2025 to Join Class Action
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal...
US FDA approves AbbVie's drug for a type of lung cancer
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.
Calls of the Day: RobinHood, UnitedHealth, Abbvie and Lowe's
The Investment Committee debate the latest Calls of the Day.
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
– EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment...
Regeneron upgraded, AbbVie downgraded as Citi reviews policy risk
Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.
AbbVie and ADARx partner to develop RNA-based therapies
Tech sector rebounds: Nvidia and Google lead market gains
Tech sector rebounds: Nvidia and Google lead market gains The US stock market is seeing a notable uptick today, with significant contributions from the technology sector. As investors navigate an incr...
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapi...
A Look Into AbbVie Inc's Price Over Earnings
In the current market session, AbbVie Inc. (NYSE: ABBV) stock price is at $188.93, after a 0.60% drop. However, over the past month, the company's stock increased by 6.84% , and in the past year, by ...
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.